Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
A Randomized, Controlled, Multi-center Phase II Study of Ivonescimab (AK112) plus Paclitaxel versus Paclitaxel with or without Ramucirumab as second-line therapy in subjects with advanced gastric or gastroesophageal junction(G/GEJ)cancer who failed immunochemotherapy
Epistemonikos ID: e44da44900b01f3b2447bd9e876f25b02c7078b4
First added on: Apr 02, 2025